Accurate diagnosis and staging are essential for the optimal management of cancer patients. Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography ( 18 F-FDG PET/CT) has emerged as a powerful imaging tool for the detection of various cancers. The combined acquisition of PET and CT has synergistic advantages over PET or CT alone and minimizes their individual limitations. It is a valuable tool for staging and restaging of some tumors and has an important role in the detection of recurrence in asymptomatic patients with rising tumor marker levels and patients with negative or equivocal findings on conventional imaging techniques. It also allows for monitoring response to therapy and permitting timely modification of therapeutic regimens. In about 27% of the patients, the course of managment is changed. This review provides guidance for oncologists/ radiotherapists and clinical and surgical specialists on the use of 18 F-FDG PET/CT in oncology.
There is evidence that 18 F-FDG PET/CT is particularly useful for detecting recurrence, especially in asymptomatic patients with rising tumor marker levels and those with negative or equivocal conventional imaging findings. Yet there are some limitations and areas of uncertainty, mainly regarding the lack of specificity of 18 F-FDG uptake and the variable avidity of some cancers for this tracer. This article reviews the main applications, advantages and limitations of 18 F-FDG PET/CT in oncology.
METHODS
A search was performed to identify mainly all published randomized controlled trials and systematic reviews in the English language literature. An additional search was performed to identify relevant unpublished systematic reviews. These publications comprised both retrospective and prospective studies of variable methodological quality. The consequences of false-positive and false-negative test results when evaluating the clinical usefulness of tests, as well as the impact of 18 F-FDG PET/CT on the management of cancer patients, were also reviewed.
noninvasive carcinomas is poor, with an overall sensitivity of only 68% for tumors of size <2 cm. 1, 2 For axillary nodal staging, 18 F-FDG PET/CT has variable sensitivity (79%-94%) and specificity (86%-92%), 3, 4 and therefore the predictive accuracy is insufficient to recommend this modality for routine use. 5 The most important current clinical applications of 18 F-FDG PET/CT in breast cancer patients are for the detection and evaluation of recurrent or metastatic disease ( Figure 2 ) and for monitoring response to therapy. 6 In a patient-based analysis, it was shown that 18 F-FDG PET/CT has a high overall sensitivity, specificity and Figure 1 . A 73-year-old woman who came for initial staging of non-small cell lung cancer. Maximum-intensity-projection (MIP) image (left panel), CT images (middle panels) and fused images (right panels) of 18F-FDG PET/CT show the primary tumor (arrow head) with mediastinal nodal metastases (black arrow). Incidental right iliac fossa small focal uptake (yellow arrow) is noted, which cross-correlated to a small soft tissue lesion in the cecum and turned out to be a synchronous primary adenocarcinoma. Table 1 . Clinical indications of 18F-FDG PET/CT in oncology (include but are not limited to the following).
• Evaluating the extent of disease in known malignancies (staging/restaging).
• Detecting tumor recurrence, in the presence of elevated tumor markers but no clinical or morphological evidence of disease.
• Searching for an unknown primary when metastatic disease is the first clinical presentation or when patients present with paraneoplastic syndrome.
• Differentiating benign from malignant lesions.
• Evaluating disease response to chemotherapy or radiotherapy.
• Selecting tumor region for biopsy guidance.
• Pre-surgical planning.
• Radiotherapy planning with therapeutic and palliative intent.
Modified from the European Association of Nuclear Medicine (EANM) and Society of Nuclear Medicine (SNM).
accuracy for the detection of locoregional recurrence (89%, 84% and 87%, respectively) and distant metastases (100%, 97% and 98%, respectively) ( Table 2 ) and is also more sensitive than the serum tumor marker CA 15-3 in detecting relapsed disease. 7 Detection of a decrease in the standardized uptake value (SUV) to a level below 55% of the baseline study is a powerful tool in monitoring histopathological response to chemotherapy for locally advanced breast cancers. Using this criterion, 18 F-FDG PET/CT was found to have a sensitivity of 100%, a specificity of 85% and an accuracy of 88% in identifying responders after the first cycle, while corresponding values after the second cycle were 83%, 94% and 91%. 8 After a single pulse of chemotherapy, 18 F-FDG PET was able to predict complete pathological response with a sensitivity of 90% and a specificity of 74%. 9 The reported overall survival in 18 F-FDG PET/CT nonresponders is 8.8 months, compared with 19.2 months in responders. 10 In the case of bone metastases, the responding bony lesion may become more sclerotic on the CT component of 18 F-FDG PET/CT while its 18 F-FDG activity reduces, which is a sign of bone healing.
Colorectal Cancer
In colorectal cancer, 18 F-FDG PET/CT plays a pivotal role in the detection of recurrent disease, the assessment of residual post-therapy masses, the localization of recurrence in patients with an unexplained rise in serum carcinoembryonic antigen (CEA) and the staging of patients before surgical resection of local recurrence and distant metastatic disease. 11 For the detection of intra-abdominal but extrahepatic colorectal recurrence, the sensitivity of 18 F-FDG PET/CT is 88%; the specificity, 94%; and accuracy, 92%. For extra-abdominal and/ or hepatic recurrence, the sensitivity is 95%; specificity, 100%; and accuracy, 99%. The overall reported average sensitivity, specificity and accuracy for detecting recurrent disease are 89%, 92% and 90%, respectively ( Table 2) . 12 The residual pelvic soft tissue abnormalities frequently seen in the tumor bed region after therapy usually complicate the detection of local recurrence by the conventional imaging techniques.
13,14 Abnormal 18 F-FDG activity in a residual pelvic soft tissue lesion after 6 months from the completion of radiotherapy most likely represents tumor recurrence, and accuracy and positive predictive value (PPV) are even higher after 12 months. 11, 15, 16 Elevated CEA levels are seen in twothirds of patients with recurrent colorectal cancer. 17-20 18 F-FDG PET/CT is recommended for patients with an unexplained increase in serum CEA level after primary curative treatment of colorectal cancer, since it changes the course of management in 59% to 68% of the patients (Figure 3) . 11,21-23 18 F-FDG PET/CT is emerging as a potentially valuable technique in radiotherapy planning, as well as in the prediction and evaluation of response to therapy. 11, 24 The use of 18 F-FDG PET/CT for preoperative radiotherapy planning in rectal cancer significantly alters both the gross tumor volume and the clinical target volume, with a mean increase in size of 25% and 4%, respectively.
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Esophageal Cancer
Endoscopic ultrasound (EUS) provides more accu- rate and cost-effective T-staging and N-staging than 18 F-FDG PET/CT and conventional CT [26] [27] [28] and remains the standard for local tumor evaluation. 29 The most important role of 18 F-FDG PET/CT in the initial staging of esophageal cancer lies in M-staging (Figure 4 ) through its ability to identify unexpected metastases (i.e., metastases not visible on conventional imaging), which are present in up to 30% of the patients. 30 18 F-FDG PET/CT has better sensitivity, specificity and accuracy (43%-78%, 93%-99% and 62%-86%, respectively) than CT and EUS for the detection of distant metastases ( Table 2) . [30] [31] [32] [33] [34] In M-staging, the addition of 20% and down-staging of 5% to 7% of the patients. 34, 35 In addition, synchronous primary tumors are identified in 5.5% of patients, of which 75% are not identified by conventional imaging. 36 Assessment of tumor response to neoadjuvant therapy by 18 F-FDG PET/CT has been found to be an important prognostic factor, 37 with a reported diagnostic accuracy of 85%; this is similar to the diagnostic accuracy of EUS (86%) and significantly higher than that of conventional CT (54%). 38 In patients with squamous cell carcinoma of the esophagus and some inoperable cases, 18 F-FDG PET/ CT plays an important role in radiotherapy planning, [39] [40] [41] with a reported modification of gross tumor volume in 56% of the patients and alteration of the planning treatment volume in 53%. 41 18 F-FDG PET is a highly sensitive tool for the detection of regional and distant recurrences, with a reported sensitivity, specificity and accuracy of 94%, 82% and 87%, respectively, in comparison to 81%, 82% and 81% for conventional imaging. Furthermore, 18 F-FDG PET depicted recurrences in 12% of the patients with negative or equivocal findings on conventional imaging.
42
Head and Neck Cancer 18 F-FDG PET/CT has an impact on the assessment of both newly diagnosed and previously treated patients with head and neck cancer. 43 18 F-FDG PET/CT alters the initial clinical staging and TNM category of the tumor in 14% to 57% of the patients when compared with CT-based evaluation alone, 44, 45 and has an accuracy of approximately 90% compared with 86% for conventional CT. 46, 47 The reported sensitivity and specificity of standard 18 F-FDG PET/CT for the detection of lymph node metastases in a per-patient analysis were 94% and 84%, respectively ( Table 2) , in comparison to 78% and 84% for conventional CT. 48 18 F-FDG PET/CT has been found to identify synchronous primaries in 8.1%, distant metastases in 15.4% and the site of an unknown primary in 73% of the patients with head and neck cancer. 46 In addition, it alters the initial management in 18% to 37% of the patients. 46, 49 The impact of 18 F-FDG PET/CT on radiotherapy planning is especially important: planning is changed in 29% of the patients, 50 with an alteration in the gross tumor volume in 57% of the patients. 45 It has been reported that the gross tumor volume is statistically significantly larger with 18F-FDG PET/CT-based assessment than with CT-based assessment. 51, 52 There is still a high risk of locoregional recurrence (18%-31%) and distant metastasis (20%-25%) despite aggressive treatment. 53, 54 The sensitivity, specificity and accuracy of 18 F-FDG PET/CT in restaging patients with head and neck cancer are 88%, 78% and 86%, respectively. 55 Postoperative, but pre-radiotherapy, 18 F-FDG PET/ CT evaluation within a median of 4 weeks after surgery has been found to alter the course of management in 15% of the patients. 56 In addition, it has a higher accuracy than conventional CT when used at 4 to 8 weeks following the end of chemoradiotherapy, with an even higher sensitivity and specificity after 8 weeks.
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Lung Cancer
Correct initial staging of non-small cell lung cancer (NSCLC) is important in distinguishing operable patients from those who are inoperable, but can benefit from neoadjuvant treatment. 58 The American College of Chest Physicians guidelines 59 recommend 18 F-FDG PET for noninvasive staging owing to the low sensitivity and specificity of the commonly used conventional CT in mediastinal nodal staging. 18 F-FDG PET/CT is a more accurate method and is the emerging standard test for preoperative diagnosis and staging of NSCLC; it changes the course of management in up to 52% of cases and has a major role in reducing the number of futile thoracotomies. [60] [61] [62] [63] Diagnostic accuracy and sensitivity of 18 F-FDG PET/CT staging of lung cancer in terms of operability have recently been reported to be 79% and 64%, respectively, in comparison to 60% and 32% for conventional staging . 64 The initial reported sensitivity and specificity for 18 F-FDG PET in mediastinal nodal assessment are 67% to 92% and 82% to 99%, respectively (Table 2) , in comparison to 25% to 71% and 66% to 98% for CT alone. Overall, the correct stage is assessed by 18 F-FDG PET in 85% to 96% of the cases as compared with 58% to 59% by conventional CT alone, and 18 F-FDG PET has a negative predictive value (NPV) of 97% (CT, 87%). [65] [66] [67] Sensitivity, specificity and accuracy of 18 F-FDG PET/CT for the depiction of malignant nodes are 85%, 84% and 84%, respectively, in comparison to 70%, 69% and 69% for CT alone. 68 The high NPV of 18 F-FDG PET/CT (up to 97%) for mediastinal disease [69] [70] [71] has led to the recommendation to omit mediastinoscopy in patients with negative mediastinal 18 F-FDG PET/CT. 70, 72, 73 However, special attention should be paid to central tumors, which have a high incidence of occult N2 disease. 74 If
18
F-FDG PET/CT is positive, then mediastinoscopy is necessary to exclude a false-positive result. 59 18 F-FDG PET/CT detects unexpected extrathoracic metastases ( Figure 5 ) in 11% to 15% of asymptomatic patients, avoiding futile surgical intervention. 70,75,76 18 F-FDG PET/CT is useful for radiation therapy planning since it provides more accurate initial staging, allowing omission of elective radiation of clinically uninvolved nodal stations. 77 In addition, its CT data may be used for radiation therapy planning if properly acquired. 78 This modality can be successfully applied to patients with limited-disease small cell lung cancer for whom the treatment is concurrent chemoradiotherapy, with a reported 24% change in the treatment field.
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Post-treatment fibrosis and scarring are common, and 18 F-FDG PET/CT is more accurate than conventional CT in detecting residual and recurrent disease, which allows more reliable treatment planning decisions. [80] [81] [82] [83] In addition, conventional CT alone has been shown to be suboptimal in mediastinal restaging after treatment. 84,85 18 F-FDG PET has sensitivity of 93% to 100% and a specificity of 89% to 92% for detecting recurrent NSCLC. [86] [87] [88] Patients with residual 18 F-FDG uptake after treatment have a poor prognosis when compared to those without residual 18 F-FDG uptake, taking into consideration the expected post-therapeutic inflammatory changes to avoid false-positive interpretation. 84 Reduction in the baseline maximum SUV on 18 F-FDG PET is predictive of a complete pathologic response with a sensitivity of 90%, a specificity of 100% and an accuracy of 96%, irrespective of the cell type or neoadjuvant treatment. 89 Indeterminate solitary pulmonary nodules (SPNs) remain a clinical dilemma. 18 F-FDG PET/CT currently should be reserved for cases where CT-guided fine-needle biopsy either is technically difficult or has been non-diagnostic. 80 Compared with CT scan, 18 F-FDG PET has similar sensitivity but better specificity in depicting malignancy in SPNs, the reported values ranging from 81% to 100% and from 63% to 100%, respectively.
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Lymphoma
18
F-FDG PET/CT is now an established standard in the initial staging, monitoring of response to therapy and restaging after treatment of patients with Hodgkin lymphoma (HL) and high-grade non-Hodgkin lymphoma (NHL). 93 The clinical utility of 18 F-FDG PET/ CT depends on the pathological subtype but not necessarily on the tumor grade. 94 18 F-FDG PET/CT shows a sensitivity of 86% and a specificity of 96%, in comparison to 81% and 41% with conventional CT alone, in disease assessment (presence or absence) of HL during both initial staging and restaging. 95 In patients with HL or high-grade NHL, the sensitivity and specificity of 18 F-FDG PET/CT for lymph node involvement are 94% and 100%, respectively, while for organ involvement they are 88% and 100% ( Table 2) . 96 False-negative scans are noted in MALT (mucosalassociated lymphoid tissue) lymphomas, which are not highly metabolically active. 97 Aggressive (high-grade) NHL typically shows more intense 18 F-FDG activity in comparison to lower-grade NHL, although there is significant overlap between them. 96 Detection of an FDGavid lesion in a documented low-grade NHL should raise the suspicion of transformation to a higher-grade lymphoma. 97, 98 Infectious and/or inflammatory diseases are known causes of false-positive 18 F-FDG PET/ CT scans, and the possibility of their presence should be entertained at interpretation. [99] [100] [101] [102] Residual post-therapy masses are seen in up to 85% of the cases of HL and up to 40% of the cases of NHL. 103, 104 Early interim 18 F-FDG PET/CT results (after two to four cycles) correlate well with event-free survival in HL (Figure 6) 105-107 and highgrade NHL. 108, 109 In high-grade NHL, the event-free survival at 2 years and 5 years has been reported to be 82% and 88.8%, respectively, for negative interim PET patients in compassion to 43% and 16.2%, respectively, for positive interim PET patients. 108, 109 In another study, the 2-year event-free survival in HL patients with negative interim 18 F-FDG PET was 95% in comparison to 12.8% in those with positive interim 18 F-FDG PET.
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Thyroid Cancer
More than 90% of thyroid cancers are differentiated, comprising papillary and follicular carcinoma. 110 In dedifferentiated thyroid cancer, recurrent or metastatic tumor cells may lose the expression of sodium iodide symporter and have a decreased ability to concentrate radioiodine. 111 A multicenter trial showed that the sensitivity of 18 F-FDG PET is 85% in patients with raised thyroglobulin and negative 131I whole-body scans. 112 In this subgroup of patients, 18 F-FDG PET/CT alters clinical management in 23% to 51% of the pateints.
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Urological Cancer
Renal cell carcinoma 
Bladder cancer
Currently there is no established role for 18 F-FDG PET/CT in the assessment of bladder cancer, since the high adjacent physiological urinary excretion of the tracer renders the signal-to-noise ratio unfavorable for lesion detection.
Gynecological Cancers
Cervical cancer 18 F-FDG PET(/CT) has a major role in preoperative staging of advanced cervical cancer and restaging after treatment. 120,121 18 F-FDG PET has a sensitivity of 86%, a specificity of 94% and an accuracy of 92% for detection of para-aortic nodal metastases in patients with advanced cervical cancer and negative abdominal CT. 122 Furthermore, preoperative evaluation with 18 F-FDG PET influences patient management in 18% of patients; while in the case of recurrent cervical cancer, 18 F-FDG PET shows an overall sensitivity of 86% to 94% and specificity of 76% to 100%. 123 The 2-year progressionfree survival rate is 86% for patients with a negative posttreatment scan in comparison to 40% for those with persistent abnormal 18 F-FDG uptake. 124 Ovarian cancer 18 F-FDG PET(/CT) has a major role in the evaluation of recurrent ovarian cancer when there is an increase in serum CA-125 and inconclusive or negative conventional (CT/MRI) imaging. 121 The reported sensitivity and PPV of 18 F-FDG PET/CT for detection of recurrent disease at least 1 cm in size are 83.3% and 93.8%, respectively. 125 
Cutaneous Melanoma
There is no role for 18 F-FDG PET/CT in early cutaneous melanoma (American Joint Committee on Cancer stages I and II). 126, 127 In advanced (AJCC stages III and IV) and recurrent cutaneous melanoma, 18 F-FDG PET shows 100% sensitivity for visceral and abdominal nodal metastases and 100% accuracy for superficial lymph node metastases, but lower sensitivity for pulmonary metastases. 128 However, the CT component of a combined PET/CT scan would allow better evaluation of pulmonary metastases. The reported rate of synchronous tumor on 18 F-FDG PET was 4.3%. 129 18 F-FDG PET results in changes in staging in 12% to 34% of the patients 130, 131 and changes in overall management in 8% to 61% of the patients.
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Brain Tumors
Sensitivity and specificity of 18 F-FDG PET/CT in evaluating low-grade and recurrent tumors and treatmentinduced changes are relatively low, mainly owing to the adjacent high physiological brain 18 F-FDG activity; however, this can be improved significantly by co-registration with magnetic resonance imaging and potentially by delayed imaging. 18 F-FDG PET/CT is capable of identifying anaplastic transformation of a documented low-grade tumor and has a prognostic value.
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Pitfalls
It is extremely important to consider some pitfalls of 18 F-FDG PET/CT imaging during scan interpretation. The ability to detect tumors depends on various factors, such as their size, metabolic activity, the surrounding background activity and the serum glucose level. Falsenegative results may be obtained in small lesions (<7 mm), in tumors with a low metabolic rate (e.g., differentiated neuroendocrine tumors, prostate cancer, hepatocellular carcinoma, MALT and mucinous adenocarcinoma), in the presence of interfering cytostatic treatments that may decrease the tumor 18 F-FDG uptake and when there is suboptimal preparation of patients with glucose intolerance or diabetes (since elevated serum glucose levels result in decreased FDG uptake in tumors owing to competitive inhibition). In addition, Figure 7 . A 62-year-old woman with history of breast cancer. The left column images (MIP and axial PET images) show the normal-intensity images, which could hide metastatic deposits and give a false-negative result due to the physiological high background intensity of the brain. The same images after reducing their intensity on the right column show the metastatic deposits.
local high physiological FDG activity (as in the brain and the genitourinary tract) can render the signal-tonoise ratio unfavorable for lesion detection (Figure 7) , and may give rise to a false-negative result by masking a malignant lesion.
On the other hand, activated macrophages, neutrophils, fibroblasts and granulation tissue show increased 18 F-FDG activity; therefore, infectious/ inflammatory processes (e.g., granulomatous diseases, abscesses, active thyroiditis), post-surgical changes (healing surgical wounds, scars, stoma, tube placement) and post-radiation changes (active fibrosis, radiation pneumonitis) may demonstrate increased 18 F-FDG activity and cause a false-positive result.
The Future
As to the evolving role of 18 F-FDG PET/CT and possible future directions for PET/CT, the need to evaluate early response to therapy remains, and there are no good imaging tools at present. Data shows that 18 F-FDG PET/CT predicts not only response to therapy, but also further hard endpoints, such as time to progression. It is likely that more well-designed and large clinical studies on 18 F-FDG PET/CT will expand its approved clinical indications in this context. Currently the majority of PET/CT investigations in oncology use 18 F-FDG (glucose metabolic marker) as a tracer. However, the changing demand to evaluate tumor angiogenesis, tumor hypoxia, tumor cell proliferation and tumor receptors, has led to the development of other specific tracers, which will get greater clinical acceptance with time.
